New Vaccine Shows Incredible Promise for Patients
One of the latest advances at Moffitt is a therapy that uses the patient’s own immune system to fight and destroy cancer. Moffitt researchers, led by physician-scientist Brian J. Czerniecki, M.D., Ph.D., are currently using this approach to create a personalized vaccine that directs an attack on the progression of breast cancer.
The vaccine is designed to help early-stage breast cancer patients who have HER2 positive disease. The HER2 protein is present in nearly one-fourth of all breast cancer tumors and is typically associated with a poor prognosis.
To further their research, Dr. Czerniecki and his team performed a clinical trial, and approximately 80 percent of the patients showed a detectable immune response.
This is great news because it means the vaccine has the potential to be a safe and effective treatment option for HER2 early-stage breast cancer patients. This discovery has led to additional larger clinical trials that could one day lead to FDA approval. And your support is making it happen.